Release Date: February 20, 2025
Expiration Date: February 20, 2026
Activity Overview
This online, on-demand virtual symposium brings together renowned experts in small cell lung cancer (SCLC) and focuses on Lambert-Eaton myasthenic syndrome (LEMS). In this educational program, these experts discuss key details about the relationship between LEMS and SCLC with case-based discussions on optimal diagnostic strategies and multidisciplinary management. The case-based format allows faculty to share practice patterns, perspectives, and key clinical data to support their decision-making process.
This educational activity is an archive of the live symposium held on January 31, 2025.
Target Audience
This educational activity is directed toward oncologists involved in the treatment and management of patients with lung cancers. Neurologists, nurse practitioners, nurses, physician assistants, pharmacists, researchers, fellows, and other health care professionals interested in the treatment of lung cancers may also participate.
Learning Objectives
Upon successful completion of this activity, you should be better prepared to:
- Recognize the clinical presentation of cancer-associated LEMS in SCLC patients
- Evaluate diagnostic protocols for confirming cancer-associated LEMS in the context of lung cancer
- Select appropriate treatments for optimal management of cancer-associated LEMS and lung cancer
- Implement safety protocols for managing adverse events in concurrent LEMS and SCLC treatment
Estelamari Rodriguez, MD, MPH
Clinical Research Lead Thoracic Site
University of Miami Miller School of Medicine
Miami, FL
Disclosures: Advisor: Amgen, AstraZeneca, Bristol Myers Squibb, Catalyst Pharmaceuticals, Daiichi Sankyo, Janssen, Novocure, Regeneron; Education Video: Amen.
Millie Das, MD
Clinical Professor, Stanford University
Chief, Oncology, VA Palo Alto Health Care System
Disclosures: Grant/Research Support: CellSight, Genentech, Merck, Novartis, Varian; Consultant: AbbVie, Amgen (uncompensated), Bristol Myers Squibb, Catalyst, Daiichi Sankyo, EMD Serono, Genentech (uncompensated), Gilead, Guardant, Janssen, Merus, Natera, Novocure, Regeneron, Sanofi/Genzyme.
Ruham Nasany, MD
Director, In-patient Neuro Oncology Service
Assistant Professor, Department of Neurology
University of Miami Miller School of Medicine
Disclosures: Honoraria: Janssen Research & Development.
Faculty, Staff, and Planners’ Disclosures
The staff of Physicians’ Education Resource®, LLC, have no relevant financial relationships with ineligible companies.
PER® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.
Off-Label Disclosure and Disclaimer
This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a healthcare professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.
GET STARTED WITH THIS PROGRAM:
Register now to gain access to this program.
Create AccountAlready Registered? Login Here